Andrea Lobo,  —

Freeline Therapeutics announced plans to leverage knowledge gained from its FLT201 gene therapy program in Gaucher disease to advance a similar candidate to treat people whose Parkinson’s is tied to mutations in the GBA1 gene. “Our GBA1-linked Parkinson’s disease program is a natural extension of our…

Following a positive safety review, Annovis Bio‘s Phase 3 clinical trial testing oral buntanetap for the treatment of early-stage Parkinson’s disease can move forward as originally designed, the company announced. That positive review came from the Data and Safety Monitoring Board (DSMB), an independent group of experts, which…

Koneksa has partnered with Beacon Biosignals to launch a clinical trial focused on advancing research in neuroscience, including Parkinson’s disease, with an aim to develop electroencephalogram (EEG) biomarkers. EEG technology has long been used to measure the brain’s electrical activity and identify evidence of neurological disorders like…

Enrollment is now complete for a Phase 3 trial of buntanetap, an oral therapy candidate from Annovis Bio that aims to improve cognitive and motor skills in early-stage Parkinson’s disease, the company has announced. Since the first participant was dosed in August 2022, more than 640 patients…

Components from tire wear, higher temperatures and age accelerate the degeneration of dopaminergic neurons in Parkinson’s disease, a new study done in nematode worms suggests. The study, “Tire components, age and temperature accelerate neurodegeneration in C. elegans models of Alzheimer’s and Parkinson’s disease,” was published in the journal…

A collaborative effort between the University of Oxford and Selvita will foster the development of potential disease-modifying therapies targeting alpha-synuclein aggregation, a key hallmark of Parkinson’s disease. The accumulation of toxic aggregates of alpha-synuclein contributes to the progressive loss of dopaminergic neurons, the nerve cells in the…

Neuronic has partnered with Santa Clara University in Silicon Valley to develop a research project to study light therapy guided by real-time brain activity. Light therapy, also called photobiomodulation, is painless and noninvasive, and uses light-emitting diodes (LEDs) to deliver near-infrared light that passes through the skin and…

h2o Therapeutics has partnered with AmerisourceBergen to commercialize Parky, a prescription mobile app that monitors symptoms in people with Parkinson’s disease, such as tremors and involuntary muscle movements. The Parky app monitors a patients’ symptoms in real time using an Apple Watch, and shares the data…

Sinopia Biosciences has selected SB-0110 as its lead clinical candidate for Parkinson’s disease after extensive preclinical studies. The move has triggered a cumulative funding of $3.3 million of its fast-track Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke. The fast-track SBIR…

The first healthy volunteer has been dosed in a clinical study that will test the safety and efficacy of Herantis Pharma’s HER-096 treatment candidate for Parkinson’s disease, the company announced in a press release. The Phase 1a clinical trial also is evaluating the ability of HER-096 to penetrate…